Search results
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 days agoRapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of NTLA-2001 for the treatment of hereditary ATTR
Circio debuts proof-of-concept for circVec gene therapy at ASGCT 2024
BioPharma-Reporter· 2 days agoThe two posters demonstrate in vivo superiority of circular RNA vs. linear mRNA-based expression. At...
Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoWave Life Sciences Ltd. (NASDAQ:WVE) Q1 2024 Earnings Call Transcript May 9, 2024 Wave Life Sciences...
Earnings call: Intellia Therapeutics reports robust Q1 progress By Investing.com
Investing.com· 5 days agoIntellia Therapeutics (NASDAQ: NASDAQ:NTLA) has made significant progress in the first quarter of...
Vertex Is Writing A New Playbook For Pharma R&D. And It’s Working.
Forbes· 23 hours agoFounded in 1989, Vertex’s rollercoaster story is most iconically characterized by the rise and fall...
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
Zacks via Yahoo Finance· 7 days agoBeam Therapeutics is also developing an in vivo base editor BEAM-302 for the treatment of alpha-1...
WAVE Life Sciences Reports First Quarter 2024 Financial Results
GuruFocus.com via Yahoo Finance· 4 days agoThe company is also preparing to initiate clinical trials for its INHBE program in obesity by the first quarter of 2025, promising an innovative approach to weight management. Moreover, WAVE ...
Kamada Ltd. Forecasted to Post Q2 2024 Earnings of $0.05 Per Share (NASDAQ:KMDA)
ETF DAILY NEWS· 5 days agoKamada Ltd. (NASDAQ:KMDA – Free Report) – Equities researchers at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for Kamada in a note issued to investors on Thursday ...